MS
CYTK icon

Maven Securities’s Cytokinetics CYTK Stock Holding History

Maven Securities’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-50,000
Closed -$1.79M – 893
2021
Q3 		$1.79M Buy
+50,000
New +$1.47M 0.06% 272
2021
Q2 		– Sell
-57,441
Closed -$1.33M – 1114
2021
Q1 		$1.33M Buy
57,441
+21,941
+62% +$469K 0.06% 314
2020
Q4 		$738K Sell
35,500
-4,500
-11% -$82.2K 0.07% 292
2020
Q3 		$882K Buy
+40,000
New +$936K 0.07% 269

Other funds holding CYTK

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Maven Securities's CYTK Position: Q4 2021 in Review

Maven Securities sold out of Cytokinetics (CYTK) in Q4 2021, closing a stake of 50,000 shares — an estimated $1.79M sold.

Maven Securities first reported a position in CYTK in Q3 2020 and held it in 4 quarters. The position peaked at $1.79M in Q3 2021. 250 funds tracked by Wall St. Rank hold CYTK as of Q4 2021.

  • Maven Securities reported no remaining Cytokinetics position as of Q4 2021 after selling out during the quarter.
  • Maven Securities sold 50,000 Cytokinetics shares in Q4 2021, an estimated $1.79M.
  • Maven Securities first reported a position in Cytokinetics in Q3 2020 and held it in 4 quarters.
  • Maven Securities's Cytokinetics position peaked at $1.79M in Q3 2021.
  • 250 funds tracked by Wall St. Rank held Cytokinetics as of Q4 2021.

Based on Maven Securities's 13F filing for Q4 2021, filed 14 Feb 2022.